Summary
Thermo Fisher Scientific Inc. (TMO) reported its third-quarter and nine-month results for the period ending September 27, 2014. The company demonstrated significant revenue growth, largely driven by the transformative acquisition of Life Technologies Corporation in February 2014, which nearly doubled the size of its Life Sciences Solutions segment. Total revenues increased by 31% year-over-year for the quarter and 29% for the nine-month period. This acquisition significantly impacted the balance sheet, with substantial increases in goodwill and acquisition-related intangible assets, alongside higher short-term and long-term obligations. Despite the integration complexities and increased debt, Thermo Fisher showed improved operating income and profitability metrics compared to the prior year, reflecting the synergistic benefits and scale advantages from the Life Technologies integration. While the company is managing a substantial debt load resulting from the acquisition, its cash flow from operations remains robust, and management expressed confidence in its ability to meet financial obligations and fund future operations. Investors should note the significant increase in acquisition-related assets and liabilities and the associated debt, which are key implications of the company's aggressive growth strategy through M&A.
Financial Highlights
57 data points| Revenue | $4.17B |
| Cost of Revenue | $1.87B |
| Gross Profit | $1.93B |
| R&D Expenses | $175.20M |
| SG&A Expenses | $1.23B |
| Operating Expenses | $3.53B |
| Operating Income | $640.30M |
| Interest Expense | $116.80M |
| Net Income | $471.60M |
| EPS (Basic) | $1.18 |
| EPS (Diluted) | $1.17 |
| Shares Outstanding (Basic) | 399.90M |
| Shares Outstanding (Diluted) | 403.70M |
Key Highlights
- 1Total revenues for the nine months ended September 27, 2014, increased by 29% to $12.40 billion, compared to $9.62 billion in the same period of 2013.
- 2The acquisition of Life Technologies Corporation, completed on February 3, 2014, significantly impacted the financial statements, resulting in a substantial increase in assets, particularly goodwill and acquisition-related intangible assets, as well as total liabilities.
- 3Operating income for the nine months ended September 27, 2014, increased by 61% to $1.86 billion from $1.15 billion in the prior year, driven by the Life Technologies acquisition and gains on business sales.
- 4Net income for the nine months ended September 27, 2014, rose to $1.29 billion from $931 million in the same period of 2013, representing a 39% increase.
- 5The company's cash flow from operating activities increased to $1.67 billion for the first nine months of 2014, up from $1.28 billion in the prior year, demonstrating strong operational cash generation.
- 6Total debt increased significantly, with long-term obligations rising to $11.39 billion from $9.50 billion at year-end 2013, reflecting financing activities related to the Life Technologies acquisition.
- 7The Life Sciences Solutions segment saw a dramatic revenue increase of 478% for the nine-month period, largely due to the inclusion of Life Technologies' results.